1. World Health Organization. Atlas: multiple sclerosis resources in the world. 2008. Available from: http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdf?ua=1 . Accessed November 13, 2014
2. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78:161–75.
3. Reynolds MW, Stephen R, Seaman C, Rajagopalan K. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13:90–8.
4. European Medicines Agency. European public assessment report: Gilenya. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002202/WC500104530.pdf . Accessed October 16, 2014.
5. US Food and Drug Administration. Teriflunomide (marketed as Aubagio) prescribing and labeling information. Latest label approved on September 12, 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf . Accessed September 9, 2013.